• SKIP TO CONTENT
  • SKIP NAVIGATION
  • Patient Resources
    • Clinical Trial Listings
    • What is Clinical Research?
    • Volunteering for a Clinical Trial
    • Understanding Informed Consent
    • Useful Resources
    • FDA Approved Drugs
  • Professional Resources
    • Research Center Profiles
    • Market Research
    • Benchmark Reports
    • FDA Approved Drugs
    • Training Guides
    • Books
    • eLearning
    • Events
    • Newsletters
    • White Papers
    • SOPs
  • White Papers
  • Clinical Trial Listings
  • Advertise
  • Sign In
  • Create Account
  • Sign Out
  • My Account
Home » Concept Life Sciences acquires CXR

Concept Life Sciences acquires CXR

August 21, 2015
CenterWatch Staff

CXR Biosciences, an investigative and exploratory toxicology company, has been acquired by Concept Life Sciences, the scientific laboratory and consultancy group.

CXR Biosciences will retain its name and operate under the Concept Life Sciences Group umbrella. All CXR staff will join the Concept Life Sciences’ Group, and CXR Biosciences CEO Paul Smith will continue to head up the business. CXR will continue to provide its customers with its investigative toxicology, exploratory toxicology and metabolism and pharmacokinetics services from its laboratory base in Dundee, U.K.

Led by Executive Chairman Michael Fort and Chief Executive Officer Alan Morgan, the Concept Life Sciences Group currently has more than 600 staff members in 11 core locations, with advanced plans for further expansion into continental Europe. The deals marks its fourth acquisition since it was formed in July 2014.

CXR Biosciences is an investigative and exploratory toxicology business. Its in-house expertise assists leading agrochemical, chemical, pharmaceutical, biotechnology and consumer products companies in resolving issues relating to the safety of compounds, and with the selection of drug and chemical candidates.

    Upcoming Events

    • 16Oct

      MAGI@home Clinical Research Conference 2023

    • 25Oct

      2023 WCG Patient Forum

    • 26Oct

      FDA in 2024: What to Expect in an Election Year

    Featured Products

    • Surviving an FDA GCP Inspection

      Surviving an FDA GCP Inspection: Resources for Investigators, Sponsors, CROs and IRBs

    • Best Practices for Clinical Trial Site Management

      Best Practices for Clinical Trial Site Management

    Featured Stories

    • Donna Snyder

      New WCG Executive Physician Outlines Goals for Clinical Research

    • Hand Shake at Meeting

      Partnership to Bolster Trials in Low Resource Regions Kicks Off

    • Guidelines-360x240.png

      Major Industry Groups Offer Feedback on ICH’s E6(R3) Guidelines

    • AsktheExpertsBadge-360x240.png

      Ask the Experts: Monitoring

    Standard Operating Procedures for Risk-Based Monitoring of Clinical Trials

    The information you need to adapt your monitoring plan to changing times.

    Learn More Here
    • About Us
    • Contact Us
    • Privacy Policy
    • Do Not Sell or Share My Data

    Footer Logo

    300 N. Washington St., Suite 200, Falls Church, VA 22046, USA

    Phone 703.538.7600 – Toll free 888.838.5578

    Copyright © 2023. All Rights Reserved. Design, CMS, Hosting & Web Development :: ePublishing